



Supplemental Figure 5. Wild-type KRAS is Amplified in Trametinib Resistant POS Cells Following Dose Escalation. (A) KRAS expression measured by RNA-Seq of POS naïve cells during chronic treatment with 10 nM trametinib. (B) Immunoblot for KRAS following treatment of trametinib naïve and trametinib resistant cells with control siRNA or siRNA targeting KRAS. (C) Quantification of KRAS expression by RNA-FISH in POS resistant (dark blue) and untreated POS (grey). (D) Rank-ordered quantification of KRAS expression by scRNA-seq in POS R1 (dark blue) and naïve control (grey).